Don't know.
From what's been said publicly they would prefer to sell products into the non-hospital, clinical podiatry space using an established sales force rather than developing their own.
They must think that realistic opportunities might become available -- it's not pie-in-the-sky, wishful thinking. It strikes me that DW is not a fantasist and is comfortable with thinking along such lines as he has deep M&A experience.
PNV - Banter and General Comments, page-11310
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.34 |
Change
-0.020(0.85%) |
Mkt cap ! $1.615B | |||
| Open | High | Low | Value | Volume |
| $2.34 | $2.37 | $2.32 | $2.004M | 857.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2441 | $2.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.34 | 19571 | 5 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.33 |
Change
-0.020 ( 1.24 %) |
||||
| Open | High | Low | Volume | ||
| $2.34 | $2.37 | $2.32 | 261156 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| PNV (ASX) Chart |